Background: Permanent interstitial brachytherapy is--in certain cases--a very successful therapeutic option, but application of radioactive implants always results in only gradually diminishing radiation exposure of persons in the patient's immediate surroundings.
Material And Methods: Using patients with clinically localized prostate cancer treated with iodine-125 ((125)I) or palladium-103 ((103)Pd) as an example, it is shown how a patient, if necessary or wished by him, can, by wearing commercially available X-ray protection shorts, reduce radiation exposure of family members in such a way that at a distance r from the patient a given dose per year is not exceeded.
Results: The computational procedures necessary for the determination of the individual periods of wearing X-ray protection clothing are provided in the form of formulae and graphics. All considerations and calculations can also be applied to other radiotherapeutic interventions involving the use of (125)I, (103)Pd or other gamma-sources.
Conclusion: If necessary, a patient with permanent radioactive implants can reduce radiation exposure of family members by wearing special X-ray protection clothing for a limited period of time. This kind of radiation protection is very efficient and considerably simpler to accomplish than a reduction of exposure time or an increase of the distance between the patient and family members.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00066-010-2073-x | DOI Listing |
Rep Pract Oncol Radiother
December 2024
Department of Biomedical Physics, Faculty of Physics, Adam Mickiewicz University, Poznań, Poland.
Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.
Material And Methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market.
Liver Int
January 2025
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Background & Aims: GD2, a member of the ganglioside (GS) family (sialic acid-containing glycosphingolipids), is a potential biomarker of cancer stem cells (CSC) in several tumours. However, the possible role of GD2 and its biosynthetic enzyme, GD3 synthase (GD3S), in intrahepatic cholangiocarcinoma (iCCA) has not been explored.
Methods: The stem-like subset of two iCCA cell lines was enriched by sphere culture (SPH) and compared to monolayer parental cells (MON).
Am J Transl Res
November 2024
Department of Radioactive Intervention, Henan No. 3 Provincial People's Hospital Zhengzhou 450006, Henan, China.
ECMO is an advanced technology for extracorporeal respiratory and circulatory support. It involves the extraction of venous blood from the patient's body, which is subsequently oxygenated within an oxygenator (or membrane lung). This oxygen-rich blood is reinfused either into veins or arteries, rapidly compensating for impaired lung and heart functionalities.
View Article and Find Full Text PDFAdv Sci (Weinh)
December 2024
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Radioactive iodine-125 (I) seed implantation, a brachytherapy technique, effectively kills tumor cells via X-rays and gamma rays, serving as an alternative therapeutic option following the failure of frontline treatments for various solid tumors. However, tumor radioresistance limits its efficacy. Hydrogen gas has anticancer properties and can enhance the efficacy of immunotherapy.
View Article and Find Full Text PDFJ R Coll Physicians Edinb
December 2024
Department of Rheumatology, Royal London Hospital, Barts Health NHS Trust, London, UK.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!